Physician profile
David S Azer
NPI 1609196930
$1,883.03
in general payments reported to CMS, 2019-2025
9 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $75.55 · 2021: $49.74 · 2022: $229 · 2023: $29.49 · 2024: $44.49 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $562 · Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $561.60 |
| Food and Beverage | $547.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $834.94 | 2025 | Senza, Vyrsa V1 |
| Boston Scientific Corporation | $396.91 | 2019-2024 | |
| Dexcom, INC. | $223.26 | 2024-2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $222.47 | 2019 | |
| Scilex Pharmaceuticals INC. | $107.51 | 2022-2023 | Ztlido |
| Horizon Therapeutics Plc | $33.75 | 2022 | |
| Grt US Holding, INC. | $29.48 | 2022 | |
| Si-Bone, INC. | $20.50 | 2019 | |
| Depuy Synthes Sales INC. | $14.21 | 2023 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Azer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.